Intellia Therapeutics Inc (NASDAQ:NTLA) shares rose 2.9% during trading on Monday . The stock traded as high as $23.47 and last traded at $22.94, with a volume of 162,752 shares trading hands. The stock had previously closed at $22.30.

NTLA has been the subject of several recent research reports. Credit Suisse Group AG initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price target for the company. Jefferies Group initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “hold” rating and a $33.00 price target for the company. Wedbush initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price target for the company. Leerink Swann initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price target for the company. Finally, Zacks Investment Research cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $35.50.

The firm’s market capitalization is $811.41 million. The stock’s 50 day moving average price is $19.13 and its 200-day moving average price is $23.07.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.